Stock FEROZ FEROZSONS LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ferozsons Laboratories Limited

Equities

FEROZ

PK0005201014

End-of-day quote Pakistan S.E.
Other stock markets
 23:00:00 25/06/2024 BST 		5-day change 1st Jan Change
240.6 PKR -0.15% Intraday chart for Ferozsons Laboratories Limited -3.22% +9.06%
04-26 Ferozsons Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
02-29 Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Its low valuation, with P/E ratio at 9.16 and 6.75 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
FEROZSONS LABORATORIES LIMITED Stock Ferozsons Laboratories Limited
+9.06% 37.62M - -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.61% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.25% 654B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.62% 337B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.44% 302B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 247B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.09% 229B
A+
NOVARTIS AG Stock Novartis AG
+13.03% 219B
B-
AMGEN INC. Stock Amgen Inc.
+8.61% 171B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
-
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. FEROZ Stock
  4. Ratings Ferozsons Laboratories Limited